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Abstract 
Cocrystals are very interesting and useful product. In this paper the main information about cocrystals is presented. It is shown 
that cocrystals are solid substances, which consist of few components mixed together. There are a lot of ways of cocrystals 
production and application. It is shown that cocrystals can be applied in medicine and pharmaceutical industry for improving 
different properties such as dissolution rate, melting point, solubility, chemical stability etc. Another way of cocrystals 
application is drug pharmacological action modification. 
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1. Introduction 
 
The definition of the term “pharmaceutical cocrystal” is still under discussion, but essentially it is a multi-
component compound that is formed between a molecular or ionic API (Active Pharmaceutical Ingredience). 
Cocrystals are solid under ambient conditions (Fig.1). Paul Pfeiffer in his book „Organische Molekulverbindungen“ 
(1922, this book were reproducted in 2012 by Publisher: Nabu Press) separated cocrystals into two categories; those 
made of inorganic:organic components, and those made only of organic components. The inorganic:organic 
cocrystals include organic molecules cocrystallized with alkali and alkaline earth salts, mineral acids, and halogens 
as in the case of the halogenated quinones. A majority of the organic:organic cocrystals contained aromatic 
compounds, with a significant fraction containing di- or trinitro aromatic compounds1.  
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Fig. 1. Schematic representation of API solvates/hydrates, cocrystals and salts2 
 
Pharmacodynamically, cocrystal former is a ballast molecule (the same applies to salts), and the GRAS (Generally 
Recognized as Safe) rules apply. Nevertheless even a cocrystal former can be an active molecule. The stoichiometric 
ratio of API and cocrystal former in a pharmaceutical cocrystal is mostly simple (1:1, 1:2, 1:3 or vice versa). 
Cocrystals are not necessarily binary compounds, ternary and quarternary cocrystals are known. Cocrystals can be 
divided into: cocrystal anhydrates, cocrystal hydrates (solvates), cocrystals of salts (unsolvated, unhydrated or 
solvated, hydrated). The borderline between salts and cocrystals is blurred and can be distinguished by the location 
of the proton between an acid and a base. In salts, carboxyl proton is moved to the hydrogen of the base while in 
cocrystals the proton remains on the carboxyl of the acid. In cases when 'pKa = pKa(base) - pKa(acid) = 0 – 3, the 
transfer of proton is ambiguous and we talk about the salt-cocrystal continuum.  
 
2. Production 
 
The preparation of cocrystals involves a number of techniques, in gas, liquid or solid phase. The most important is 
the joint cocrystal growth from solution or joint solid state grinding, often with the addition of a small amount of a 
“molecular lubricant” (methanol, cyclohexan, chlorophorm etc.), so-called liquid assisted grinding. Furthermore, co-
crystals can be synthesized by evaporation, sublimation, melting, sonication etc. It often holds that identical starting 
components may not yield the same product under different cocrystallization techniques3.  
A multitude of other methods exist in order to produce cocrystals. Crystallizing with a molar excess of one 
cocrystal former may produce a cocrystal by a decrease in solubility of that one component. Another method to 
synthesize cocrystals is to conduct the crystallization in a slurry. As with any crystallization, solvent considerations 
are important. Changing the solvent will change the intermolecular interactions and possibly lead to cocrystal 
formation. Also, by changing the solvent, phase considerations may be utilized. The role of a solvent in nucleation 
of cocrystals remains poorly understood but critical in order to obtain a cocrystal from solution4. The intermolecular 
interactions and resulting crystal structures can generate physical and chemical properties that differ from the 
properties of the individual components. Such properties include melting point, solubility, chemical stability, and 
mechanical properties.  
Some cocrystals have been observed to exist as polymorphs, which may display different physical properties 
depending on the form of the crystal5.  
 
As an example of cocrystallization, production of “Coffein citrate“ cocrystal is shown on figure 2.  
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Fig. 2. An overview of solid-state reactions of hydrated and nonhydrated forms of caffeine and citric acid6 
 
The cocrystallization potential of some active molecules is studied in detail, e.g. carbamazepine, itraconazole, 
piroxicam, norfloxacin, fluoxetin, caffein and others. The reason is to achieve a wide variation in solid-state 
properties of APIs. These efforts stem from principles of supramolecular chemistry and crystal engineering to affect 
the properties of API through the “bottom up” approach. This is illustrated in the following examples.  
By the cocrystallization of antifungal drug itraconazole with 1,4-dicarboxylic acids (succinic acid, L-tartaric acid 
or L-malic acid) a modification of the dissolution profile is achieved compared to the amorphous form of 
itraconazole (Sporanox, Janssen-Cilag)7. A 1:1 carbamazepine/saccharin cocrystal compared to polymorph III of 
carbamazepine (anticonvulsant Tegretol, Novartis) shows no polymorphous behaviour and is not prone to 
hydration8. The cocrystallization of pregabalin with S- mandelic acid separates from the mixture of R and S isomers 
only the (1:1) cocrystal (S)-pregabalin/(S)-mandelic acid. This technology is used by Pfizer in manufacturing dosage 
form Lyrica9. The cocrystals of paracetamol show an improved tablet formation ability than free paracetamol, 
polymorf I (Panadol, GlaxoSmithKline)10. Caffein tends to form hydrates at high RH (relative humidity) while its 
cocrystals with  oxalic acid or malonic acid do not have this unwanted property (never form hydrates)9. However, 
general trends of variation of properties during the transition from APIs to their cocrystals are not so far evident 
because fundamental causes of cocrystallization are not known so far. 
3. Application 
A key question concerning the practical application of a cocrystal of a commercial API is whether the cocrystal is 
in some sense a physical mixture and hence might fall within current compendial guidelines, or whether the 
cocrystal should be regarded as a new chemical entity with all the concomitant safety and toxicological testing such 
substances require. The USA Food and Drug Administration (FDA) have released draft guidance on the regulatory 
classification of pharmaceutical cocrystals for applicants for New Drug Applications (NDAs) and Abbreviated New 
Drug Applications (ANDAs). The FDA defines cocrystals as “solids that are crystalline materials composed of two 
or more molecules in the same crystal lattice” - the implication is that it is two or more types of molecules that are 
referred to here11. 
The FDA also regards cocrystals as dissociable “API-excipient” complexes, blurring the boundary between 
cocrystals and physical mixtures. This guidance has generated a strong response from some researchers in the 
cocrystal field who propose alternative, yet also potentially controversial definitions that distinguish 
multicomponent APIs and their cocrystals from solvates and hydrates.  
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Among many recent patents relating to potential commercial cocrystal products, the possibility of combining two 
active ingredients in a single cocrystal is an interesting one and has been claimed in the cocrystallization of 
quercetin (a plant-derived flavonoid, used as a nutritional supplement and reputed to offer some anti-cancer 
properties) with antidiabetic agents such as metformin or tolazamide. The combination drug has been suggested to 
have physical properties and biological activity that are distinct from the individual properties of the two 
components. Interesting research pointing the way to applications of cocrystals in the modification of drug 
pharmacological action has been reported for insulin, a peptide hormone used for the treatment of diabetic patients. 
Insulin has poor oral bioavailability and is commonly injected. Human insulin has been cocrystallised with a 
lipophilically modified, closely related insulin analogue octanoyl-N-LysB29-human insulin. The lipophilic 
formulation was designed to provide a slow release profile compatible with an improved physiological insulin 
profile12. 
 
4. Conclusion 
 
Application of pharmaceutical cocrystals is very important alternative way to improve the bioavailability of poorly 
water-soluble drugs, especially for these neutral compounds or those having weakly ionizable groups.  
Although, the definition of the term “pharmaceutical cocrystal” is still under discussion, it is clear that this 
substances are very useful, and it is important to explore new cocrystals of an API to improve or obtain some 
properties, such as habit, bulk density, solubility, compressability, friability, melting point, hygroscopy and 
dissolution rate.  
Another way for cocrystals application is modification of drug pharmacological action, for example insulin. 
Cocrystals investigation and production are very interesting for researchers and very useful for medics and 
pharmacologists. 
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